Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bio-Path stock

Own Bio-Path stock in just a few minutes.

Bio-Path Holdings, Inc is a biotechnology business based in the US. Bio-Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Bio-Path

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BPTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bio-Path share price

Use our graph to track the performance of BPTH stocks over time.

Bio-Path shares at a glance

Information last updated 2021-04-30.
52-week range$3.12 - $9.40
50-day moving average $6.68
200-day moving average $5.06
Wall St. target price$12.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.19

Buy Bio-Path shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio-Path stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio-Path financials

Gross profit TTM $0
Return on assets TTM -34.84%
Return on equity TTM -60.2%
Profit margin 0%
Book value $3.32
Market capitalisation $40.9 million

TTM: trailing 12 months

Shorting Bio-Path shares

There are currently 233,129 Bio-Path shares held short by investors – that's known as Bio-Path's "short interest". This figure is 208.7% up from 75,517 last month.

There are a few different ways that this level of interest in shorting Bio-Path shares can be evaluated.

Bio-Path's "short interest ratio" (SIR)

Bio-Path's "short interest ratio" (SIR) is the quantity of Bio-Path shares currently shorted divided by the average quantity of Bio-Path shares traded daily (recently around 1.2 million). Bio-Path's SIR currently stands at 0.19. In other words for every 100,000 Bio-Path shares traded daily on the market, roughly 190 shares are currently held short.

However Bio-Path's short interest can also be evaluated against the total number of Bio-Path shares, or, against the total number of tradable Bio-Path shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Path's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Bio-Path shares in existence, roughly 30 shares are currently held short) or 0.0337% of the tradable shares (for every 100,000 tradable Bio-Path shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Path.

Find out more about how you can short Bio-Path stock.

Bio-Path share dividends

We're not expecting Bio-Path to pay a dividend over the next 12 months.

Have Bio-Path's shares ever split?

Bio-Path's shares were split on a 1:20 basis on 17 January 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio-Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio-Path shares which in turn could have impacted Bio-Path's share price.

Bio-Path share price volatility

Over the last 12 months, Bio-Path's shares have ranged in value from as little as $3.12 up to $9.4. A popular way to gauge a stock's volatility is its "beta".

BPTH.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Path's is 2.0524. This would suggest that Bio-Path's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Bio-Path overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Frequently asked questions

What percentage of Bio-Path is owned by insiders or institutions?
Currently 0.668% of Bio-Path shares are held by insiders and 7.09% by institutions.
How many people work for Bio-Path?
Latest data suggests 10 work at Bio-Path.
When does the fiscal year end for Bio-Path?
Bio-Path's fiscal year ends in December.
Where is Bio-Path based?
Bio-Path's address is: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
What is Bio-Path's ISIN number?
Bio-Path's international securities identification number is: US09057N3008
What is Bio-Path's CUSIP number?
Bio-Path's Committee on Uniform Securities Identification Procedures number is: 04744L106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site